• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Alkermes Plc (NQ: ALKS )

    26.51 +1.51 (+6.04%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Jul 24, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Alkermes Plc

    < Previous 1 2 3 4 5 6 7 8 9 10 Next >
    The 3 Best Biotech Stocks to Invest in for Big Gains in 2024
    These pivotal biotech stocks for gains are charting the future of medicine and investment growth in 2024 offering powerful returns 
    Via InvestorPlace
    3 Top Pharma Stocks to Buy Now: February 2024
    Discover why these three pharma stocks should be on your buy list in February 2024 - they could be your ticket to explosive portfolio growth. 
    Via InvestorPlace
    For those who appreciate growth without the sticker shock, NASDAQ:ALKS is worth considering.
    Don't overlook ALKERMES PLC (NASDAQ:ALKS)—a stock with solid growth prospects and a reasonable valuation. 
    Via Chartmill
    Axsome Therapeutics Stock Showing Leadership, Earns 91 RS Rating
    Axsome Therapeutics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating. 
    Via Investor's Business Daily
    Cassava Sciences Stock Continues Showing Rising Relative Strength
    Cassava Sciences sees its Relative Strength Rating move into the elite 90-plus level. 
    Via Investor's Business Daily
    The 3 Most Undervalued Biotech Stocks to Buy in January
    These are a number of undervalued biotech companies that investor should possibly look to add to their portfolios. 
    Via InvestorPlace
    NASDAQ:ALKS, a growth stock which is not overvalued.
    Investors seeking growth at a reasonable cost should explore NASDAQ:ALKS. 
    Via Chartmill
    Decoding 5 Analyst Evaluations For Alkermes
    Via Benzinga
    Delving into NASDAQ:ALKS's Growth Prospects.
    High growth, ROE and beating expectations for NASDAQ:ALKS: growth investors may appreciate this. 
    Via Chartmill
    Earnings Scheduled For February 15, 2024
    Companies Reporting Before The Bell • Cognex (NASDAQ:CGNX) is estimated to report quarterly earnings at $0.10 per share on revenue of $188.59 million. 
    Via Benzinga
    Alkermes's Earnings Outlook
    Via Benzinga
    CRISPR Therapeutics Stock Shows Rising Relative Strength, Hits 90+
    CRISPR Therapeutics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating. 
    Via Investor's Business Daily
    NASDAQ:ALKS is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.
    Investors should take notice ofALKERMES PLC (NASDAQ:ALKS)—it offers a great deal for the fundamentals it presents. 
    Via Chartmill
    7 Biotech Stocks Fighting America’s Deadliest Diseases
    Although the human condition can be alarmingly frail at times, these groundbreaking biotech stocks are aiming to right the ship. 
    Via InvestorPlace
    Is NASDAQ:ALKS suited for growth investing?
    Why the growth investor may take a look at NASDAQ:ALKS. 
    Via Chartmill
    Madrigal Pharmaceuticals Stock Shows Rising Relative Strength
    A Relative Strength Rating upgrade for Madrigal Pharmaceuticals shows improving technical performance. 
    Via Investor's Business Daily
    NASDAQ:ALKS, an undervalued stock with good fundamentals.
    Investors should take notice ofALKERMES PLC (NASDAQ:ALKS)—it offers a great deal for the fundamentals it presents. 
    Via Chartmill
    Why the growth investor may take a look at ALKERMES PLC (NASDAQ:ALKS).
    High growth, ROE and beating expectations for NASDAQ:ALKS: growth investors may appreciate this. 
    Via Chartmill
    ALKERMES PLC (NASDAQ:ALKS) showing high EPS and FCF growth while beating expectations
    Why the growth investor may take a look at NASDAQ:ALKS. 
    Via Chartmill
    For those who appreciate value investing, NASDAQ:ALKS is a compelling option with its solid fundamentals.
    Investors should take notice ofALKERMES PLC (NASDAQ:ALKS)—it offers a great deal for the fundamentals it presents. 
    Via Chartmill
    For those who appreciate growth without the sticker shock, NASDAQ:ALKS is worth considering.
    Looking for growth without the hefty price tag? Consider ALKERMES PLC (NASDAQ:ALKS). 
    Via Chartmill
    When you look at NASDAQ:ALKS, it's hard to ignore the strong fundamentals, especially considering its likely undervaluation.
    ALKERMES PLC (NASDAQ:ALKS) is a prime example of a stock that offers more than what meets the eye in terms of fundamentals. 
    Via Chartmill
    Uber Will Join The S&P 500 Index. The Stock Is Jumping.
    The ride-hailing giant will join the index as part of a quarterly rebalancing. 
    Via Investor's Business Daily
    Topics Stocks
    Exposures US Equities
    For those who appreciate growth without the sticker shock, NASDAQ:ALKS is worth considering.
    Investors seeking growth at a reasonable cost should explore NASDAQ:ALKS. 
    Via Chartmill
    Where Alkermes Stands With Analysts
    Via Benzinga
    NASDAQ:ALKS: good value for what you're paying.
    Investors should take notice ofALKERMES PLC (NASDAQ:ALKS)—it offers a great deal for the fundamentals it presents. 
    Via Chartmill
    NASDAQ:ALKS—A High-Growth Stock Gearing Up for Its Next Upward Move.
    Is ALKERMES PLC (NASDAQ:ALKS) on the Verge of a Major Breakout as a Strong Growth Stock? 
    Via Chartmill
    Why Is Mural Oncology (MURA) Stock Up 59% Today?
    Mural Oncology stock is climbing higher on Friday as the company's shares bounce back from a dip yesterday during its public debut. 
    Via InvestorPlace
    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
    It's time to start the final day of trading this week with a breakdown of the biggest pre-market stock movers for Friday morning! 
    Via InvestorPlace
    3 Growth Stocks Set to Dominate the Decade
    Here are three growth stocks to buy that are poised to dominate the decade. Add them to your portfolio for long-term financial success. 
    Via InvestorPlace
    < Previous 1 2 3 4 5 6 7 8 9 10 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.